Tobacco and Public Health - TCSC Indonesia

JACK E. HENNINGFIELD AND NEAL L. BENOWITZ 145
Molander, L., Hansson, A., Lunell, E., Alainentalo, L., Hoffmann, M., and Larsson, R. (2001).
Pharmacokinetics of nicotine in kidney failure. Clinical Pharmacology and Therapeutics,
68, 250–60
National Institute on Drug Abuse (1984). Drug abuse and drug abuse research, first triennial report to
congress.National Institute on Drug Abuse, Rockville, MD.
National Cancer Institute (1998). Cigars: health effects and trends. Smoking and tobacco control
monograph No. 9.U.S. Department of Health and Human Services, Public Health Service,
National Institutes of Health National Cancer Institute.
Newhouse, P. A., and Hughes, J. R. (1991). The role of nicotine and nicotinic mechanisms in
neuropsychiatric disease. British Journal of Addiction, 86 (5), 521–6.
Newhouse, P. A., Potter, A., and Levin, E. D. (1997). Nicotinic system involvement in Alzheimer’s and
Parkinson’s-diseases—implications for therapeutics. Nicotine and Neurodegenerative Diseases,
11 (3), 206–28.
O’Brien, C. P. (1996). Drug addiction and drug abuse. In: Goodman and Gilman’s The
Pharmacological Basis of Therapeutics (ed. J. G. Hardman, A. G. Gilman, and L. E. Limbird),
pp. 557–77. McGraw-Hill, New York.
Oscarson, M. (2001). Genetic polymorphism in the cytochrome P450 2A6 gene: Implications for
interindividual differences in nicotine metabolism. Drug Metab. Disp., 29, 91–5.
Paterson, D., and Nordberg, A. (2000). Neuronal nicotinic receptors in the human brain. Progress in
Neurobiology, 61 (1), 75–111
Perkins, K. (2002). Chronic tolerance to nicotine in humans and its relationship to tobacco
dependence. Nicotine and Tobacco Research, 4, 405–22.
Perez-Stable, E. J., Herrera, B., Jacob, P., III, and Benowitz, N. L. (1998). Nicotine metabolism and
intake in black and white smokers. Journal of the American Medical Association, 280, 152–6.
Perkins, K. A., Grobe, J. E., Epstein, L. H., Caggiula, A. R., Stiller, R. L., and Jacob, R. G. (1993).
Chronic and acute tolerance to subjective effects of nicotine. Pharmacology Biochemistry and
Behavior, 45, 375–81.
Pickworth, W. B., Bunker, E. B., and Henningfield, J. E. (1994). Transdermal nicotine: reduction of
smoking with minimal abuse liability. Psychopharmacology, 115, 9–14.
Pickworth, W. B., Heishman, S. J., and Henningfield, J. E. (1995). Relationships between EEG and
performance during nicotine withdrawal and administration. In: Brain Imaging of Nicotine and
Tobacco Smoking (ed. E. F. Domino), NPP Books, Ann Arbor, pp. 275–87.
Rose, J. E., Sampson, A., Levin, E. D., and Henningfield, J. E. (1989). Mecamylamine increases nicotine
preference and attenuates nicotine discrimination. Pharmacology Biochemistry and Behavior,
32, 933–8.
Rose, J. E., Behm, F. M., and Levin, E. D. (1993). Role of nicotine dose and sensory cues in the
regulation of smoke intake. Pharmacology Biochemistry and Behavior, 44, 891–900.
Royal College of Physicians of London (2000). Nicotine addiction in Britain: a report of the Tobacco
Advisory Group of the Royal College of Physicians. Royal College of Physicians, London, U.K.
Royal Society of Canada (1989). Tobacco nicotine and addiction: a committee report prepared at the
request of the Royal Society of Canada. Royal Society of Canada, Ottawa, Canada.
Santos, M. D., Alkondon, M., Pereira, E. F., Aracava, Y., Eisenberg, H. M., Maelicke, A., and
Albuquerque, E. X. (2002). The nicotinic allosteric potentiating ligand galantamine facilitates
synaptic transmission in the mammalian central nervous system. Molecular Pharmacology,
61 (5), 1222–34.
Shiffman, S., Mason, K. M., and Henningfield, J. E. (1998). Tobacco dependence treatments: review
and prospectus. Annual Review of Public Health, 19, 335–58.